Open AccessHydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection
Author(s) -
Arnold Samuel L.M.,
Buckner Frederick
Publication year - 2020
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12797
Subject(s) - hydroxychloroquine , medicine , pandemic , intensive care medicine , coronavirus , clinical trial , repurposing , chloroquine , randomized controlled trial , disease , covid-19 , malaria , immunology , infectious disease (medical specialty) , ecology , biology
In less than six months, COVID-19 has spread from a marketplace in Wuhan, China to over 150 countries and territories of the world. Therapeutics are desperately needed to reduce the morbidity and mortality of this pandemic disease. It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.